Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINERVA: Abemaciclib + Endocrine Therapy in HR+/HER2- Breast Cancer
NCT05362760Phase 4Recruiting
- Sponsor
- Prof. Wolfgang Janni
- Start
- Apr 2022
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Prof. Wolfgang Janni. Primary endpoint: Progression Free Survival at 48 months. Started Apr 2022; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05362760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362760.